A Study of a New Induction and Dosing Schedule for Sublocade in Opioid Use Disorder (BRIDGE)
BRIDGE Study: Buprenorphine XR Real-world Induction, Dosing, and Gradual Evaluation
This study is looking at a new way to start Sublocade, a monthly injectable medicine already approved in Canada for opioid use disorder. Right now, most people start Sublocade with two doses of 300 mg, one month apart. This study is testing a different, more gradual approach: a smaller dose (50 mg) on Day 1, a second small dose (50 mg) on Day 7, and then the regular dose (300 mg) on Day 14.
The study team wants to find out whether this gradual approach helps people transitioning from methadone, or people who have used buprenorphine before, get started on treatment more easily. Everyone in the study follows the same schedule, and no one gets a placebo (an inactive treatment).
Participants will get study visits on Day 1, Day 7, and Day 14, along with short daily check-ins about how they're feeling for about 4 weeks, and some questionnaires about their quality of life and treatment satisfaction. The study is being done at one clinic in Calgary, Alberta.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Sublocade (buprenorphine extended-release) is a Health Canada-approved subcutaneous injection for the management of moderate to severe opioid use disorder in adults (DIN 02483084, 100 mg; DIN 02483092, 300 mg). The currently approved induction regimen consists of 300 mg for the first injection and 300 mg for the second injection, administered one month apart, with subsequent monthly maintenance dosing.
This study evaluates a modified induction and titration schedule intended to characterize an alternative approach for patients transitioning from methadone treatment or with prior buprenorphine exposure. Participants receive 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14, using the same approved product and formulation, prepared via partial-volume administration from the 100 mg pre-filled syringe for the Day 1 and Day 7 doses.
The primary objective is to determine the proportion of participants who complete this induction schedule without discontinuation due to withdrawal symptoms or adverse events. Secondary objectives include characterizing daily withdrawal symptom trajectory (via the Subjective Opiate Withdrawal Scale), and changes in Addiction Severity Index, Quality of Life, PROPr health utility, and Treatment Satisfaction scores from baseline to Week 4.
This is a prospective, single-arm, open-label interventional study with no randomization or control arm; outcomes are compared descriptively to existing standard-of-care induction practice as a historical reference. The study is conducted at a single site (The Smart Clinic, Calgary, Alberta) with a planned enrollment of 50-100 adult participants.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Navneet Singh Khosa, MD
- Phone Number: 403-769-0111
- Email: nkhosa@smartc.ca
Study Contact Backup
- Name: Ravneet Kaur Sidhu, BSN
- Phone Number: 4037690111
- Email: rsidhu@smartc.ca
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Currently receiving methadone treatment, OR active opioid use disorder with prior exposure to buprenorphine
- Willingness and ability to provide informed consent to participate
Exclusion Criteria:
- No diagnosis of opioid use disorder and no prior buprenorphine exposure
- Known intolerance or hypersensitivity to buprenorphine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Modified Induction Schedule
All participants receive buprenorphine extended-release (Sublocade) by subcutaneous injection: 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14. |
Sublocade (buprenorphine extended-release), a Health Canada-approved subcutaneous injection (DIN 02483084, 100 mg; DIN 02483092, 300 mg). Administered as 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Induction Completion Rate
Time Frame: Day 14
|
Proportion of participants who complete the Day 1, Day 7, and Day 14 dosing schedule without discontinuation due to withdrawal symptoms or adverse events. |
Day 14
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Jospeh Tcherkezian, PHD, SMART Clinic
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HREBA.CTC-26-0111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
No formal individual participant data (IPD) sharing plan has been established for this study at this time. This is a single-site, investigator-initiated study, and any future decision regarding data sharing would need to account for participant privacy protections under Alberta's Health Information Act and Personal Information Protection Act, as well as the terms of the study's funding agreement with Indivior Canada Inc.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.